L
Lars Damstrup
Researcher at Merck KGaA
Publications - 8
Citations - 326
Lars Damstrup is an academic researcher from Merck KGaA. The author has contributed to research in topics: Cancer & DNA damage. The author has an hindex of 5, co-authored 8 publications receiving 220 citations.
Papers
More filters
Journal ArticleDOI
Clinical development of new drug-radiotherapy combinations
Ricky A. Sharma,Ruth Plummer,Julie K Stock,Tessa A Greenhalgh,O. Ataman,Stephen Kelly,Robert Clay,Richard Adams,Richard D. Baird,Lucinda Billingham,Sarah Brown,Sean Buckland,Helen Bulbeck,Anthony J. Chalmers,Glen Clack,Aaron N Cranston,Lars Damstrup,Roberta Ferraldeschi,Martin Forster,Golec Julian M C,Russell M Hagan,Emma Hall,Axel-R Hanauske,Kevin J. Harrington,Tom Haswell,Maria A. Hawkins,Timothy M Illidge,Hazel Jones,Andrew S. Kennedy,Fiona McDonald,Thorsten Melcher,James P B O'Connor,John Pollard,Mark P Saunders,David Sebag-Montefiore,Melanie Smitt,John Staffurth,Ian J. Stratford,Stephen R. Wedge +38 more
TL;DR: The CTRad Working Group's consensus recommendations to increase the number of novel drugs being successfully registered in combination with radiotherapy to improve clinical outcomes for patients with cancer are highlighted.
Journal ArticleDOI
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.
Mark T. J. van Bussel,Ahmad Awada,Maja J.A. de Jonge,Morten Mau-Sørensen,Dorte Nielsen,Patrick Schöffski,Henk M.W. Verheul,Barbara Sarholz,Karin Berghoff,Samer El Bawab,Mirjam Kuipers,Lars Damstrup,Ivan Diaz-Padilla,Jan H.M. Schellens +13 more
TL;DR: Peposertib was well-tolerated and demonstrated modest efficacy in unselected tumours; the MTD was not reached; the RP2D was declared as 400 mg BID.
Journal ArticleDOI
Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.
Eric Van Cutsem,Manuel Hidalgo,Igor Bazin,Jean-Luc Canon,Elena Poddubskaya,Nebojsa Manojlovic,Michele Milella,Dejan Radenkovic,Chris Verslype,Wei Guo,Lars Damstrup,Pascal Hammel +11 more
TL;DR: Pimasertib (Pim) is a selective, non-competitive MEK 1/2 inhibitor with potent antitumor activity in preclinical models with constitutive MAPK activation in metastatic pancreatic cancer.
Journal ArticleDOI
A phase Ia/Ib trial of the DNA-PK inhibitor M3814 in combination with radiotherapy (RT) in patients (pts) with advanced solid tumors: Dose-escalation results.
Baukelien van Triest,Lars Damstrup,Johan Falkenius,Volker Budach,Esther G.C. Troost,Michael A. Samuels,Juergen Debus,Morten Sorensen,Karin Berghoff,Rainer Strotman,Mark T. J. van Bussel,Sanjay Goel,Poul F. Geertsen +12 more
TL;DR: The combination of RT and DNA-PK inhibition (DNA-PKi) inhibits the activity of DNA-dependent protein kinase, which regulates one of the major pathways responsible for repair of DNA double-strand breaks.
Journal ArticleDOI
A multicenter phase I trial of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814 in patients with solid tumors.
Mark T. J. van Bussel,Morten Mau-Soerensen,Lars Damstrup,Dorte Nielsen,Henk M.W. Verheul,Philippe Aftimos,Maja J.A. de Jonge,Karin Berghoff,Jan H.M. Schellens +8 more
TL;DR: This data indicates that treatment with EMTs that induce double-strand breaks, which are the source of DNA damage, may be a viable alternative to chemotherapy for some types of cancer.